Choi, Joon Young
Yoo, Kwang Ha
Jung, Ki-Suck
Kim, Victor
Rhee, Chin Kook
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (U01 HL089897 and U01 HL089856)
COPD Foundation (NCT00608764)
Korea National Institute of Health (2016ER670100, 2016ER670101, 2016ER670102, 2018ER67100, 2018ER67101, 2018ER67102, and 202104044B8-00)
Article History
Received: 11 March 2024
Accepted: 13 June 2024
First Online: 17 June 2024
Declarations
:
: Ethical approval was obtained from the ethics committee of each medical center participating in the KOCOSS and COPDGene cohort studies, including KONKUK University Medical Center (IRB No. KHH1010338). Written informed consent was collected from all patients. All methods were performed according to relevant guidelines and regulations.
: Not applicable.
: CK Rhee received consulting/lecture fees from MSD, AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, Sanofi, and Bayer.In the last 3 years, VK has received consultancy fees from Galvanize Therapeutics and AstraZeneca, less than $5,000 USD total. None of these consultancies are a conflict of interest in relation to this manuscript.